Glimda-MV 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, mitigating postprandial hyperglycemia. The synergistic action of these three agents targets multiple pathophysiological defects of type 2 diabetes, providing comprehensive glycemic management. Glimda-MV 2 Tablet SR is indicated for patients inadequately controlled on monotherapy or dual therapy and aims to improve both fasting and postprandial blood glucose levels. The sustained-release formulation ensures a gradual release of active ingredients, enhancing patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin and Voglibose. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. This medication should be used under medical supervision, considering contraindications such as renal impairment, hepatic dysfunction, and hypersensitivity to any component.